

Examination Result Report

Sample bar code: 1401659829

Hospital: Renji Hospital, Shanghai Jiao Tong University School of Medicine
 Patient name: Caiyun CHEN
 Inpatient/Outpatient No.:
 Tel.:
 Clinical Diagnosis:

Department:
 Age:
 Ward/ward area:
 Receiving time: 26 August 2025 10:19:35

Specimen type: Venous serum
 Specimen condition:
 Sampling time:

Bed No.:

Examination Item	Results	Indication	Unit	Reference Value	Examination Method
1 Measurement of Infliximab Blood Concentration	3.9		μg/ml	See result indications 1, 2, 3, 4	Immunochromatography
2 Measurement of Serum Concentration of Anti-Infliximab Antibodies	<4		ng/ml	See result indication 5	Immunochromatography

※ This examination result is only responsible for the specimens tested. In case of any questions, please propose within seven days!

Examined by: Yaqian YIN

Reviewed by:

Examined at: 26 August 2025 13:27:08

Reported at: 26 August 2025 16:16:51

Address: 4/F, Building 3, No. 51, Jinsigang Road, Guoxiang, Wuzhong District, Suzhou

Tel.: 0512-80821756

Special Seal for Report of Suzhou HeRuIBD Medical Laboratory (sealed)

Result Indications

1. When treating inflammatory bowel disease (IBD), according to the Chinese Experts Consensus on Therapeutic Drug Monitoring of Inflammatory Bowel Disease, the effective trough concentration of infliximab is 3-7 μg/mL, and a higher concentration within this effective range is associated with better clinical outcomes [1].
2. When treating ankylosing spondylitis (AS), responders have higher infliximab blood concentrations compared to non-responders (8.2 μg/mL vs. 6.3 μg/mL) [2].
3. When treating rheumatoid arthritis (RA), a median serum infliximab trough concentration greater than 1 μg/mL is significantly associated with improvements in the ACR20 response rate, serum C-reactive protein (CRP) levels, the number of tender joints, and the number of swollen joints [3][4].
4. When treating psoriasis (Ps), the median range of serum infliximab trough concentrations is 1-4 μg/mL [5]. A concentration greater than 1 μg/mL is significantly associated with an improvement in the Psoriasis Area and Severity Index 75 (PASI75) response [6].
5. An anti-infliximab antibody concentration of 20-30 ng/mL represents the cutoff value for distinguishing between positive and negative results and may not necessarily affect the efficacy of infliximab [7]. When the anti-infliximab antibody concentration exceeds 70 ng/mL, it may be associated with infliximab resistance [8].

References:

- [1] Chinese Experts Consensus on Therapeutic Drug Monitoring of Inflammatory Bowel Disease [J]. Chinese Journal of Inflammatory Bowel Diseases, 2018 (04): 253-254-255-256-257-258-259.
- [2] Papamichael K, et al. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert rev clin Immunol.2019 Aug; 15(8): 837-848.
- [3] Mahboob U Rahman, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis, Ann Rheum Dis 2007;66:1233-1238.
- [4] E. William St. Clair, et al. The Relationship Of serum Infliximab Concentrations to Clinical improvement in Rheumatoid Arthritis, Arthritis Rheum.2002 Jun; 46(6): 1451-9.
- [5] Kristian Reich, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet 2005; 366:1367-74.
- [6] Jennifer s Gall, et al. Infliximab for the treatment of plaque psoriasis. Biologics: Targets & Therapy 2008;2(1) 115-124.
- [7] Bauman LE, et al. improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric inflammatory Bowel Disease, Inflamm? Bowel? Dis.2019pii: izz143.
- [8] Doucoure EI, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic disease, Arthritis Res Ther.? 2011 Jun 27;13(3): R105.



Certified Translation (from Chinese into English, source document: electronic copy)

I, Yuanjie Gu, NAATI Certified Translator between Chinese and English (both directions), certify that this is a true and accurate translation of the text provided on the original document.

NAATI Practitioner ID: CPN0ZO95Z

E-mail: justina_guyuanjie@126.com



样品条形码: 1401659829
标本类型: 静脉血清
标本情况:
采样时间:
接收时间: 2025-08-26 10:19:35

医院: 上海交通大学医学院附属仁济医院
病人姓名: 陈采鋆
住院号/门诊号:
联系电话:
临床诊断:
科室:
性别:
年龄:
送检医生:
病房/区:
床号:

检查项目	结果	提示	单位	参考值	检测方法
1 英夫利西单抗血药浓度测定	3.9		μg/ml	见结果提示1, 2, 3, 4	免疫层析
2 抗英夫利西单抗抗体血清浓度测定	<4		ng/ml	见结果提示5	免疫层析

※本检验结果仅对所检验的标本负责, 如有疑问请在七天内提出!

检验人: 尹雅倩

审核人: 尹雅倩

检验日期: 2025-08-26 13:27:08

报告时间: 2025-08-26 16:16:51



地址: 苏州市吴中区郭巷金丝港路51号3号楼4楼

电话: 0512-80821756

结果提示

1. 治疗炎症性肠病(IBD)时, 中国炎症性肠病治疗药物监测专家共识意见: 英夫利西有效谷浓度为3-7ug/mL, 在有效谷浓度范围内, 浓度越高临床结局越好【1】。
2. 治疗强直性脊柱炎(AS)时, 有应答者相比失应答者有更高的英夫利西血药浓度 (8.2ug/mL vs 6.3ug/mL) 【2】。
3. 治疗类风湿性关节炎(RA)时, 血清中位英夫利西谷浓度大于1ug/mL与ACR20指数、血清CRP、触痛关节数和肿胀关节数等改善显著相关【3】【4】。
4. 治疗银屑病(Ps)时, 血清中位英夫利西谷浓度中位数范围1-4ug/mL【5】。大于1ug/mL与PASI75改善显著相关【6】。
5. 抗英夫利西抗体浓度20-30ng/mL是区分阴阳性的临界值, 并不一定影响英夫利西药效【7】。当抗英夫利西抗体浓度 > 70ng/mL时, 可能与英夫利西耐药相关【8】。

参考文献:

- 【1】中国炎症性肠病治疗药物监测专家共识意见[J].中华炎症性肠病杂志,2018(04):253-254-255-256-257-258-259.
- 【2】Papamichael K,et al.Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019 Aug;15(8):837-848.
- 【3】Mahboob U Rahman,et al.Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:1233-1238.
- 【4】E.William St. Clair,et al.The Relationship Of Serum Infliximab Concentrations to Clinical Improvement in Rheumatoid Arthritis. Arthritis Rheum. 2002 Jun;46(6):1451-9.
- 【5】Kristian Reich,et al.Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
- 【6】Jennifer S Gall,et al. Infliximab for the treatment of plaque psoriasis. Biologics: Targets & Therapy 2008;2(1) 115-124.
- 【7】Bauman LE,et al.Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Inflamm?Bowel?Dis.2019;pii: izz143.
- 【8】Ducourau E1,et al.Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic disease. Arthritis Res Ther.?2011 Jun 27;13(3):R105.